A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70012 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Amanda Long und 7 weiteren Autor:innen. Beteiligte Einrichtung: Taiho Oncology, Inc., Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Drug Interactions, ATP Binding Cassette Transporter, Subfamily G, Member 2, Rosuvastatin Calcium, Neoplasm Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Futibatinib, an inhibitor of fibroblast growth factor receptor 1–4, is approved for the treatment of patients with advanced cholangiocarcinoma with FGFR2 fusions/rearrangements. In this phase I drug–drug interaction study, the effects of futibatinib on P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) substrates, and of P‐gp inhibition on futibatinib pharmacokinetics (PK) were investigated in healthy adults aged 18–55 years. In part 1, 20 participants received digoxin (P‐gp substrate) and rosuvastatin (BCRP substrate). Following a ≥10‐day washout, futibatinib was administered for 7 days, with digoxin and rosuvastatin coadministered on the third day. In part 2, 24 participants received futibatinib. Following a ≥3‐day washout, quinidine (P‐gp inhibitor) was administered for 4 days, with futibatinib coadministered on day 4. Blood samples were collected predose and for 24 (futibatinib), 72 (rosuvastatin), and 120 h (digoxin) postdose. Urine samples (digoxin) were collected predose and for 120 h postdose. PK parameters were compared between treatments using analysis of variance. Coadministration with futibatinib had no effect on the PK of digoxin and rosuvastatin, and coadministration with quinidine had minimal effects on the PK of futibatinib. Differences in C max and AUC with and without futibatinib and quinidine, respectively, were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Taiho Oncology, Inc., Princeton, New Jersey, USA.
- Taiho Pharmaceutical Co., Ltd, Tsukuba, Ibaraki, Japan.
- Celerion, Lincoln, Nebraska, USA.
ORCID-Profile: Amanda Long, Ziv Machnes, Nanae Hangai, Volker Wacheck
Zitieren
APA
Long, A., Yamamiya, I., Valentine, M., Machnes, Z., Hangai, N., Anderson, B., Wacheck, V., & Gao, L. (2024). A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib. Clinical and Translational Science. https://doi.org/10.1111/cts.70012
Vancouver
Long A, Yamamiya I, Valentine M, Machnes Z, Hangai N, Anderson B, et al. A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib. Clinical and Translational Science. 2024. doi:10.1111/cts.70012
BibTeX
@article{Long2024,
author = {Long, Amanda and Yamamiya, Ikuo and Valentine, Michelle and Machnes, Ziv and Hangai, Nanae and Anderson, Bailey and Wacheck, Volker and Gao, Ling},
title = {A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70012}
}
EUVIMED